Boston Scientific reports loss as COVID-19 slams demand for medical devices

Published On 2020-10-31 05:30 GMT   |   Update On 2021-11-23 11:52 GMT

New Delhi: Boston Scientific Corp swung to a loss in the third quarter from profit a year ago, as demand for its medical devices was hurt by the ongoing COVID19 pandemic.The Marlborough, Massachusetts-based company said on Wednesday its sales of medical devices dropped 3.7% to $2.58 billion.Earlier this year, the company withdrew its 2020 profit forecast, citing uncertainties due to the...

Login or Register to read the full article

New Delhi: Boston Scientific Corp swung to a loss in the third quarter from profit a year ago, as demand for its medical devices was hurt by the ongoing COVID19 pandemic.

The Marlborough, Massachusetts-based company said on Wednesday its sales of medical devices dropped 3.7% to $2.58 billion.

Earlier this year, the company withdrew its 2020 profit forecast, citing uncertainties due to the COVID-19 pandemic.

Rival Abbott Laboratories, however, raised its 2020 profit forecast last week on strong COVID-19 testing revenue and a recovery in its medical device business.

Excluding items, Boston Scientific earned 37 cents per share in the third quarter.

Net sales fell 1.8% to $2.66 billion.

Net loss attributable to Boston Scientific was $169 million, or 12 cents per share, in the quarter ended Sept 30, compared with net earnings of $126 million, or 9 cents per share, last year.


Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News